<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JVMS</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Veterinary Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0916-7250</issn>
      <issn pub-type="epub">1347-7439</issn>
      <publisher>
        <publisher-name>The Japanese Society of Veterinary Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25131949</article-id>
      <article-id pub-id-type="pmc">4272992</article-id>
      <article-id pub-id-type="publisher-id">14-0001</article-id>
      <article-id pub-id-type="doi">10.1292/jvms.14-0001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Internal Medicine</subject>
          <subj-group>
            <subject>Note</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Imatinib Mesylate plus Hydroxyurea Chemotherapy for Cerebellar Meningioma in
a Belgian Malinois Dog</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>JUNG</surname>
            <given-names>Hae-Won</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>LEE</surname>
            <given-names>Hee-Chun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>KIM</surname>
            <given-names>Ji-Hyun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>JANG</surname>
            <given-names>Hyo-Mi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MOON</surname>
            <given-names>Jong-Hyun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>SUR</surname>
            <given-names>Jung-Hyang</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>HA</surname>
            <given-names>Jeongim</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>JUNG</surname>
            <given-names>Dong-In</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref rid="cor1" ref-type="corresp">
            <sup>*</sup>
          </xref>
        </contrib>
        <aff id="aff1"><label>1)</label>Institute of Animal Medicine, College of Veterinary
Medicine, Gyeongsang National University, Jinju 660&#x2013;701, South Korea</aff>
        <aff id="aff2"><label>2)</label>Department of Pathobiology, Small Animal Tumor Diagnostic
Center, College of Veterinary Medicine, Konkuk University, Seoul 143&#x2013;701, South
Korea</aff>
        <aff id="aff3"><label>3)</label>Department of Cell and Developmental Biology, School of
Dentistry, DRI and Brain Korea 21 Program, Seoul National University, Seoul 110&#x2013;749, South
Korea</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>Correspondence to: Jung, D.-I., Institute of Animal
Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju 660&#x2013;701,
South Korea. e-mail: <email xlink:href="jungdi@gnu.ac.kr">jungdi@gnu.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2014</year>
      </pub-date>
      <volume>76</volume>
      <issue>11</issue>
      <fpage>1545</fpage>
      <lpage>1548</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2014 The Japanese Society of Veterinary Science</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>ABSTRACT</title>
        <p>An 8-year-old intact male
Belgian Malinois, weighing 37.2 kg, was referred for evaluation due to right side facial
paresis, ataxia and a 2-month history of decreased cognitive ability. Physical and
neurological examinations revealed mild depression, left-sided head tilt, right-sided
facial paresis and ataxia. A well-demarcated, broad-based cerebellar mass and hyperostosis
were found on CT imaging of the brain. Based on these CT findings, a cerebellar meningioma
was strongly suspected. Hydroxyurea and prednisolone were administered; after 4 weeks,
there was reduction in mass size as compared to initial CT results. However, the mass size
was found to have grown 6 weeks after hydroxyurea treatment. We then prescribed a
combination of imatinib mesylate and hydroxyurea. Two weeks following combination
treatment, the mass size had reduced significantly. The mass continuously decreased in
size until the patient died during anesthesia. Cerebellar transitional meningioma was
confirmed by histopathologic examination. To the author&#x2019;s knowledge, this is the first
reported case of imatinib mesylate plus hydroxyurea therapy for the treatment of
meningioma in veterinary medicine.</p>
      </abstract>
      <kwd-group>
        <kwd>canine</kwd>
        <kwd>hydroxyurea</kwd>
        <kwd>imatinib mesylate</kwd>
        <kwd>meningioma</kwd>
        <kwd>tyrosine kinase inhibitor</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>An 8-year-old intact male Belgian Malinois, weighing 37.2 kg, was referred to the Gyeongsang
National University Animal Medical Center for evaluation of right-sided facial paresis, ataxia
and a 2-month history of decreased cognitive ability. The patient had no history of exposure
to toxins or head trauma as well as no prior medical problems. Physical and neurological
examinations showed mild depression, left-sided head tilt, right-sided facial paresis and
ataxia. Complete blood counts and serum biochemical examinations, radiography and urinalysis
were unremarkable. A computed tomography (CT) scan (Somatom Emotion Duo, Siemens AG, Munich,
Germany) of the brain was performed to rule out a structural brain lesion. Pre- and
post-contrast CT images were taken. The right dorsal cerebellum contained a mass with
peripheral contrast enhancement and an internal hypoattenuating lesion. The mass was
extra-axial, round and smoothly marginated. The mass had a broad base along the right
tentorium cerebelli, which appeared thickened when compared to the left adjacent bone (<xref ref-type="fig" rid="fig_001">Fig. 1A</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Serial post-contrast CT images (A to E) and MR image (F) after chemotherapy. A) At
presentation (mass volume was 8.47 cm<sup>3</sup>), B) 4 weeks (4.27 cm<sup>3</sup>) and
C) 10 weeks (6.56 cm<sup>3</sup>) after initial treatment of prednisolone and
hydroxyurea. D) 2 weeks (3.26 cm<sup>3</sup>) and E) 8 weeks (2.63 cm<sup>3</sup>) after
initiation of the imatinib and hydroxyurea. F) Post-contrast T1-weighted MR image 10
days after last CT examination (panel E) showed a dural tail sign (short arrow).</p></caption><graphic xlink:href="jvms-76-1545-g001"/></fig>). These findings were most consistent with a meningioma of the cerebellum. Results of
the CSF analysis indicated an increased nucleated cell count of 48 cells/<italic>&#xB5;l</italic>
(reference range, 0&#x2013;5 cells/<italic>&#xB5;l</italic>), and cytological examination showed
monocytoid cell population. Based on the results of the CT scan and CSF analysis, the patient
was tentatively diagnosed with a cerebellar meningioma.</p>
    <p>Management with prednisolone (Prednisolone<sup>&#xAE;</sup>, Korea Pharma, Seoul, Korea; 1 mg/kg,
per oral twice in a day) and hydroxyurea (Hydrin<sup>&#xAE;</sup>, Korea United Pharm., Seoul,
Korea; 50 mg/kg, per oral every other day) was initiated with gradual improvement in clinical
signs [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>,
<xref rid="r15" ref-type="bibr">15</xref>]. CT images were evaluated at presentation and 4,
10, 12 and 18 weeks after initial treatment to assess the patient&#x2019;s response to therapy. Four
weeks after initial treatment, ataxia and facial paresis had improved. A CT was performed, and
all images were retrieved to the Lucion image post processing system (Infinitt Technology,
Seoul, Korea). The volumes of the mass in the post-contrast images were then measured with the
auto-tracking tool. When compared to the initial CT result (<xref ref-type="fig" rid="fig_001">Fig. 1A</xref>; 8.47 cm<sup>3</sup>), cerebellar mass size was significantly reduced in the
2nd CT (4 weeks post-treatment) (<xref ref-type="fig" rid="fig_001">Fig. 1B</xref>; 4.27
cm<sup>3</sup>). Prednisolone and hydroxyurea administration were continued; however, mild
ataxia and depression reoccurred 6 weeks after the 2nd CT. The 3rd CT (10 weeks
post-treatment) indicated an increase in mass size (<xref ref-type="fig" rid="fig_001">Fig.
1C</xref>; 6.56 cm<sup>3</sup>). We suggested new chemotherapeutic trial to the owner, and
it was accepted. Imatinib mesylate (Glivec<sup>&#xAE;</sup>, Novartis, Stein, Switzerland; 8 mg/kg,
per oral once in a day) was then added to the prednisolone and hydroxyurea therapy. Two weeks
after initiation of the imatinib plus hydroxyurea therapy, neurological signs improved, and
the 4th CT (12 weeks post-treatment) indicated a significant decrease in mass size (<xref ref-type="fig" rid="fig_001">Fig. 1D</xref>; 3.26 cm<sup>3</sup>). We maintained the
imatinib plus hydroxyurea therapy for 6 weeks and then reevaluated mass size. The 5th CT (18
weeks post-treatment) showed a decrease in mass size (<xref ref-type="fig" rid="fig_001">Fig.
1E</xref>; 2.63 cm<sup>3</sup>). Ten days following this CT examination, MR images of the
brain (APERTO 0.4, Hitachi Medical Co., Tokyo, Japan) were obtained that revealed that the
mass had marked contrast enhancement with a focal hypointense area within. The mass appeared
to extend along the dura, and the surrounding meninges appeared thickened (<xref ref-type="fig" rid="fig_001">Fig. 1F</xref>). Unfortunately, the patient arrested during
anesthesia and expired. Because the patient was well controlled under chemotherapy with
imatinib plus hydroxyurea, we suspected that the patient died with sudden cardiac and
respiratory depression during general anesthesia.</p>
    <p>On necropsy, a well-defined mass was located in the right cerebellar region (<xref ref-type="fig" rid="fig_002">Fig. 2A and 2B</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p>Necropsy, histopathological and immunohistochemical findings of the present case. A
well-defined mass is located in the right cerebellar area (A and B; arrows).
Histopathology indicated transitional meningioma (C). Spindle and polygonal tumor cells
are observed, and concentric whorl patterns predominate (C: &#xD7; 400). Immunohistochemistry
for PDGFR-&#x3B1; demonstrated positive staining in the cytoplasm and perinuclear dot-like
pattern in the spindle cell arranged in a whorl (D: &#xD7; 600).</p></caption><graphic xlink:href="jvms-76-1545-g002"/></fig>). Based on histopathological findings, the present patient was definitively diagnosed
with transitional cerebellar meningioma (<xref ref-type="fig" rid="fig_002">Fig. 2C</xref>).
Platelet-derived growth factor receptors (PDGFR)-&#x3B1; rabbit anti-human polyclonal (aa1035-1053)
antibody (LifeSpan Bioscience, Seattle, WA, U.S.A.) was used to identify the expression of
PDGFR in the meningioma. Immunohistochemistry for PDGFR-&#x3B1; demonstrated positive staining in
the cytoplasm and perinuclear dot-like pattern in the spindle cell arranged in a whorl (<xref ref-type="fig" rid="fig_002">Fig. 2D</xref>).</p>
    <p>Meningioma is the most common primary brain tumor in dogs [<xref rid="r10" ref-type="bibr">10</xref>]. Generally, treatment for canine meningioma patients entails surgery, radiation
therapy, chemotherapy or combination therapy [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r17" ref-type="bibr">17</xref>]. Most
meningiomas in human medicine are treated surgically, and recurring tumors are treated with
radiation therapy and repeated surgical resection [<xref rid="r10" ref-type="bibr">10</xref>].
Surgery and/or radiation therapy are also common typical therapeutic procedures in veterinary
medicine [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r4" ref-type="bibr">4</xref>,
<xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r10" ref-type="bibr">10</xref>].
However, there are times when surgery or radiation therapy is not an option in canine
meningioma cases, because of the deep location of the tumors, patient age, costs, ethical
reasons or other complicated diseases [<xref rid="r10" ref-type="bibr">10</xref>]. For those
patients, medical therapy, such as corticosteroids, antiepileptic drugs and chemotherapeutic
agents can provide a good quality of life and prolong survival times. There were few reports
of chemotherapy for meningiomas in veterinary medicine until recently [<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r17" ref-type="bibr">17</xref>]. According to previous reports,
hydroxyurea and lomustine showed beneficial effects for meningioma in both human and
veterinary patients [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r17" ref-type="bibr">17</xref>].</p>
    <p>Most of the meningiomas, regardless of grade, express PDGFR [<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r18" ref-type="bibr">18</xref>]. Some meningiomas also express
platelet-derived growth factors (PDGF) [<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r18" ref-type="bibr">18</xref>]. Furthermore, PDGFR expression is also increased in
some brain tumors, such as glioma, glioblastoma mutiforme and ependymoma [<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r12" ref-type="bibr">12</xref>, <xref rid="r14" ref-type="bibr">14</xref>]. Imatinib
mesylate is known as an inhibitor of PDGFR, Bcr-Abl, c-KIT and c-Fms tyrosine kinase [<xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r18" ref-type="bibr">18</xref>]. Recently, several reports demonstrated that imatinib
mesylate could be a treatment option for various brain tumors [<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r18" ref-type="bibr">18</xref>]. In veterinary medicine, imatinib
mesylate has been used in some dogs and cats to treat mast cell tumors or vaccine-associated
sarcomas [<xref rid="r9" ref-type="bibr">9</xref>]. The recommended dose of imatinib mesylate
is 5&#x2013;10 mg/kg per oral once in a day [<xref rid="r9" ref-type="bibr">9</xref>]. In the present
case, we tentatively diagnosed cerebellar meningioma and started treatment with a steroid and
hydroxyurea. According to one previous report [<xref rid="r15" ref-type="bibr">15</xref>],
tumor cases treated palliatively (especially tumor located in cerebellum, pons or medulla) had
a poor prognosis. Although a few reports [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r17" ref-type="bibr">17</xref>] indicated that hydroxyurea could be a good treatment
option in meningioma cases, in our experience, some meningioma cases did not show a response.
The tumor size reduced significantly after 4 weeks of hydroxyurea therapy in the present case.
However, the tumor increased in size, and clinical signs worsened despite maintenance of
hydroxyurea therapy. One previous report [<xref rid="r18" ref-type="bibr">18</xref>] insisted
that combination therapy with imatinib mesylate and hydroxyurea could be more effective in
meningiomas when compared to single imatinib mesylate therapy. We decided to use this
combination therapy of imatinib mesylate and hydroxyurea and achieved a good result. The
present patient expired during anesthesia and therefore, showed a relatively shorter survival
time. However, this case demonstrated the beneficial effect of imatinib mesylate plus
hydroxyurea therapy in cases with cerebellar meningioma.</p>
    <p>To the author&#x2019;s knowledge, this is the first reported case of the use of imatinib mesylate
plus hydroxyurea therapy for meningioma in veterinary medicine.</p>
  </body>
  <back>
    <ack>
      <p>This research was supported by Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and
Technology (2011-0008358).</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Axlund</surname><given-names>T. W.</given-names></name><name><surname>McGlasson</surname><given-names>M. L.</given-names></name><name><surname>Smith</surname><given-names>A. N.</given-names></name></person-group><year>2002</year>. <article-title>Surgery alone or in combination with
radiation therapy for treatment of intracranial meningioma in dogs: 31 cases
(1989&#x2013;2002)</article-title>. <source><italic>J. Am. Vet. Med.
Assoc.</italic></source><volume>221</volume>: <fpage>1597</fpage>&#x2013;<lpage>1600</lpage>.
<pub-id pub-id-type="pmid">12479332</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Desjardins</surname><given-names>A.</given-names></name><name><surname>Quinn</surname><given-names>J. A.</given-names></name><name><surname>Vredenburgh</surname><given-names>J. J.</given-names></name><name><surname>Sathornsumetee</surname><given-names>S.</given-names></name><name><surname>Friedman</surname><given-names>A. H.</given-names></name><name><surname>Herndon</surname><given-names>J. E.</given-names></name><name><surname>McLendon</surname><given-names>R. E.</given-names></name><name><surname>Provenzale</surname><given-names>J. M.</given-names></name><name><surname>Rich</surname><given-names>J. N.</given-names></name><name><surname>Sampson</surname><given-names>J. H.</given-names></name><name><surname>Gururangan</surname><given-names>S.</given-names></name><name><surname>Dowell</surname><given-names>J. M.</given-names></name><name><surname>Salvado</surname><given-names>A.</given-names></name><name><surname>Friedman</surname><given-names>H. S.</given-names></name><name><surname>Reardon</surname><given-names>D. A.</given-names></name></person-group><year>2007</year>. <article-title>Phase II study of imatinib mesylate and
hydroxyurea for recurrent grade III malignant gliomas</article-title>.
<source><italic>J. Neurooncol.</italic></source><volume>83</volume>:
<fpage>53</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11060-006-9302-2</pub-id><pub-id pub-id-type="pmid">17245623</pub-id></mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Fakhrai</surname><given-names>N.</given-names></name><name><surname>Neophytou</surname><given-names>P.</given-names></name><name><surname>Dieckmann</surname><given-names>K.</given-names></name><name><surname>Nemeth</surname><given-names>A.</given-names></name><name><surname>Prayer</surname><given-names>D.</given-names></name><name><surname>Hainfellner</surname><given-names>J.</given-names></name><name><surname>Marosi</surname><given-names>C.</given-names></name></person-group><year>2004</year>. <article-title>Recurrent spinal ependymoma showing
partial remission under imatinib</article-title>. <source><italic>Acta Neurochir.
(Wien)</italic></source><volume>146</volume>: <fpage>1255</fpage>&#x2013;<lpage>1258</lpage>.
doi: <pub-id pub-id-type="doi">10.1007/s00701-004-0374-5</pub-id><pub-id pub-id-type="pmid">15365794</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Greco</surname><given-names>J. J.</given-names></name><name><surname>Aiken</surname><given-names>S. A.</given-names></name><name><surname>Berg</surname><given-names>J. M.</given-names></name><name><surname>Monette</surname><given-names>S.</given-names></name><name><surname>Bergman</surname><given-names>P. J.</given-names></name></person-group><year>2006</year>. <article-title>Evaluation of intracranial meningioma
resection with a surgical aspirator in dogs: 17 cases (1996&#x2013;2004)</article-title>.
<source><italic>J. Am. Vet. Med. Assoc.</italic></source><volume>229</volume>:
<fpage>394</fpage>&#x2013;<lpage>400</lpage>. <pub-id pub-id-type="pmid">16881832</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Jung</surname><given-names>D. I.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Kang</surname><given-names>B. T.</given-names></name><name><surname>Lim</surname><given-names>C. Y.</given-names></name><name><surname>Park</surname><given-names>E. H.</given-names></name><name><surname>Sur</surname><given-names>J. H.</given-names></name><name><surname>Seo</surname><given-names>M. H.</given-names></name><name><surname>Hahm</surname><given-names>D. H.</given-names></name><name><surname>Park</surname><given-names>H. M.</given-names></name></person-group><year>2006</year>. <article-title>Long-term chemotherapy with lomustine of
intracranial meningioma occurring in a Miniature Schnauzer</article-title>.
<source><italic>J. Vet. Med. Sci.</italic></source><volume>68</volume>:
<fpage>383</fpage>&#x2013;<lpage>386</lpage>. doi: <pub-id pub-id-type="doi">10.1292/jvms.68.383</pub-id><pub-id pub-id-type="pmid">16679732</pub-id></mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Jung</surname><given-names>D. I.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Kang</surname><given-names>B. T.</given-names></name><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name><name><surname>Lim</surname><given-names>C. Y.</given-names></name><name><surname>Jeong</surname><given-names>S. W.</given-names></name><name><surname>Park</surname><given-names>H. M.</given-names></name></person-group><year>2006</year>. <article-title>Acquired cervical syringomyelia secondary
to brainstem meningioma in a Maltese dog</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>68</volume>: <fpage>1235</fpage>&#x2013;<lpage>1238</lpage>.
doi: <pub-id pub-id-type="doi">10.1292/jvms.68.1235</pub-id><pub-id pub-id-type="pmid">17146188</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Jung</surname><given-names>D. I.</given-names></name><name><surname>Lim</surname><given-names>C. Y.</given-names></name><name><surname>Kang</surname><given-names>B. T.</given-names></name><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Yoo</surname><given-names>J. H.</given-names></name><name><surname>Park</surname><given-names>H. M.</given-names></name></person-group><year>2008</year>
<article-title>Long-term chemotherapy with hydroxyurea
in a dog with suspected intracranial meningioma</article-title>. <source><italic>J. Vet.
Clin.</italic></source><volume>25</volume>:
<fpage>512</fpage>&#x2013;<lpage>515</lpage>.</mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Klopp</surname><given-names>L. S.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name></person-group><year>2009</year>. <article-title>Endoscopic-assisted intracranial tumor
removal in dogs and cats: Long-term outcome of 39 cases</article-title>.
<source><italic>J. Vet. Intern. Med.</italic></source><volume>23</volume>:
<fpage>108</fpage>&#x2013;<lpage>115</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1939-1676.2008.0234.x</pub-id><pub-id pub-id-type="pmid">19175729</pub-id></mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>London</surname><given-names>C. A.</given-names></name></person-group><year>2009</year>. <article-title>Tyrosine kinase inhibitors in veterinary
medicine</article-title>. <source><italic>Top. Companion Anim.
Med.</italic></source><volume>24</volume>: <fpage>106</fpage>&#x2013;<lpage>112</lpage>. doi:
<pub-id pub-id-type="doi">10.1053/j.tcam.2009.02.002</pub-id><pub-id pub-id-type="pmid">19732728</pub-id></mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Motta</surname><given-names>L.</given-names></name><name><surname>Mandara</surname><given-names>M. T.</given-names></name><name><surname>Skerritt</surname><given-names>G. C.</given-names></name></person-group><year>2012</year>. <article-title>Canine and feline intracranial
meningiomas: An updated review</article-title>. <source><italic>Vet.
J.</italic></source><volume>192</volume>: <fpage>153</fpage>&#x2013;<lpage>165</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tvjl.2011.10.008</pub-id><pub-id pub-id-type="pmid">22104505</pub-id></mixed-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Newton</surname><given-names>H. B.</given-names></name><name><surname>Slivka</surname><given-names>M. A.</given-names></name><name><surname>Stevens</surname><given-names>C.</given-names></name></person-group><year>2000</year>. <article-title>Hydroxyurea chemotherapy for unresectable
or residual meningioma</article-title>. <source><italic>J.
Neurooncol.</italic></source><volume>49</volume>: <fpage>165</fpage>&#x2013;<lpage>170</lpage>.
doi: <pub-id pub-id-type="doi">10.1023/A:1026770624783</pub-id><pub-id pub-id-type="pmid">11206012</pub-id></mixed-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Reardon</surname><given-names>D. A.</given-names></name><name><surname>Egorin</surname><given-names>M. J.</given-names></name><name><surname>Quinn</surname><given-names>J. A.</given-names></name><name><surname>Rich</surname><given-names>J. N.</given-names></name><name><surname>Gururangan</surname><given-names>S.</given-names></name><name><surname>Vredenburgh</surname><given-names>J. J.</given-names></name><name><surname>Desjardins</surname><given-names>A.</given-names></name><name><surname>Sathornsumetee</surname><given-names>S.</given-names></name><name><surname>Provenzale</surname><given-names>J. M.</given-names></name><name><surname>Herndon</surname><given-names>J. E.</given-names><suffix>2nd</suffix></name><name><surname>Dowell</surname><given-names>J. M.</given-names></name><name><surname>Badruddoja</surname><given-names>M. A.</given-names></name><name><surname>McLendon</surname><given-names>R. E.</given-names></name><name><surname>Lagattuta</surname><given-names>T. F.</given-names></name><name><surname>Kicielinski</surname><given-names>K. P.</given-names></name><name><surname>Dresemann</surname><given-names>G.</given-names></name><name><surname>Sampson</surname><given-names>J. H.</given-names></name><name><surname>Friedman</surname><given-names>A. H.</given-names></name><name><surname>Salvado</surname><given-names>A. J.</given-names></name><name><surname>Friedman</surname><given-names>H. S.</given-names></name></person-group><year>2005</year>. <article-title>Phase II study of imatinib mesylate plus
hydroxyurea in adults with recurrent glioblastoma multiforme</article-title>.
<source><italic>J. Clin. Oncol.</italic></source><volume>23</volume>:
<fpage>9359</fpage>&#x2013;<lpage>9368</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2005.03.2185</pub-id><pub-id pub-id-type="pmid">16361636</pub-id></mixed-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Reardon</surname><given-names>D. A.</given-names></name><name><surname>Norden</surname><given-names>A. D.</given-names></name><name><surname>Desjardins</surname><given-names>A.</given-names></name><name><surname>Vredenburgh</surname><given-names>J. J.</given-names></name><name><surname>Herndon</surname><given-names>J. E.</given-names><suffix>2nd</suffix></name><name><surname>Coan</surname><given-names>A.</given-names></name><name><surname>Sampson</surname><given-names>J. H.</given-names></name><name><surname>Gururangan</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>K. B.</given-names></name><name><surname>McLendon</surname><given-names>R. E.</given-names></name><name><surname>Norfleet</surname><given-names>J. A.</given-names></name><name><surname>Lipp</surname><given-names>E. S.</given-names></name><name><surname>Drappatz</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>P. Y.</given-names></name><name><surname>Friedman</surname><given-names>H. S.</given-names></name></person-group><year>2012</year>. <article-title>Phase II study of Gleevec<sup>&#xAE;</sup>
plus hydroxyurea (HU) in adults with progressive or recurrent
meningioma</article-title>. <source><italic>J.
Neurooncol.</italic></source><volume>106</volume>:
<fpage>409</fpage>&#x2013;<lpage>415</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11060-011-0687-1</pub-id><pub-id pub-id-type="pmid">21938530</pub-id></mixed-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Reardon</surname><given-names>D. A.</given-names></name><name><surname>Desjardins</surname><given-names>A.</given-names></name><name><surname>Vredenburgh</surname><given-names>J. J.</given-names></name><name><surname>Herndon</surname><given-names>J. E.</given-names><suffix>2nd</suffix></name><name><surname>Coan</surname><given-names>A.</given-names></name><name><surname>Gururangan</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>K. B.</given-names></name><name><surname>McLendon</surname><given-names>R.</given-names></name><name><surname>Sathornsumetee</surname><given-names>S.</given-names></name><name><surname>Rich</surname><given-names>J. N.</given-names></name><name><surname>Lipp</surname><given-names>E. S.</given-names></name><name><surname>Janney</surname><given-names>D.</given-names></name><name><surname>Friedman</surname><given-names>H. S.</given-names></name></person-group><year>2012</year>. <article-title>Phase II study of gleevec plus
hydroxyurea in adults with progressive or recurrent low-grade glioma</article-title>.
<source><italic>Cancer</italic></source><volume>118</volume>:
<fpage>4759</fpage>&#x2013;<lpage>4767</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.26541</pub-id><pub-id pub-id-type="pmid">22371319</pub-id></mixed-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Rossmeisl</surname><given-names>J. H.</given-names></name><name><surname>Jones</surname><given-names>J. C.</given-names></name><name><surname>Zimmerman</surname><given-names>K. L.</given-names></name><name><surname>Robertson</surname><given-names>J. L.</given-names></name></person-group><year>2013</year>. <article-title>Survival time following hospital
discharge in dogs with palliatively treated primary brain tumors</article-title>.
<source><italic>J. Am. Vet. Med. Assoc.</italic></source><volume>242</volume>:
<fpage>193</fpage>&#x2013;<lpage>198</lpage>. <pub-id pub-id-type="pmid">23276095</pub-id></mixed-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Schrell</surname><given-names>U. M.</given-names></name><name><surname>Rittig</surname><given-names>M. G.</given-names></name><name><surname>Anders</surname><given-names>M.</given-names></name><name><surname>Koch</surname><given-names>U. H.</given-names></name><name><surname>Marschalek</surname><given-names>R.</given-names></name><name><surname>Kiesewetter</surname><given-names>F.</given-names></name><name><surname>Fahlbusch</surname><given-names>R.</given-names></name></person-group><year>1997</year>. <article-title>Hydroxyurea for treatment of unresectable
and recurrent meningiomas. Decrease in the size of meningiomas in patients treated with
hydroxyurea</article-title>. <source><italic>J.
Neurosurg.</italic></source><volume>86</volume>: <fpage>840</fpage>&#x2013;<lpage>844</lpage>.
doi: <pub-id pub-id-type="doi">10.3171/jns.1997.86.5.0840</pub-id><pub-id pub-id-type="pmid">9126900</pub-id></mixed-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Tamura</surname><given-names>S.</given-names></name><name><surname>Tamura</surname><given-names>Y.</given-names></name><name><surname>Ohoka</surname><given-names>A.</given-names></name><name><surname>Hasegawa</surname><given-names>T.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name></person-group><year>2007</year>. <article-title>A canine case of skull base meningioma
treated with hydroxyurea</article-title>. <source><italic>J. Vet. Med.
Sci.</italic></source><volume>69</volume>: <fpage>1313</fpage>&#x2013;<lpage>1315</lpage>. doi:
<pub-id pub-id-type="doi">10.1292/jvms.69.1313</pub-id><pub-id pub-id-type="pmid">18176033</pub-id></mixed-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Wen</surname><given-names>P. Y.</given-names></name><name><surname>Yung</surname><given-names>W. K.</given-names></name><name><surname>Lamborn</surname><given-names>K. R.</given-names></name><name><surname>Norden</surname><given-names>A. D.</given-names></name><name><surname>Cloughesy</surname><given-names>T. F.</given-names></name><name><surname>Abrey</surname><given-names>L. E.</given-names></name><name><surname>Fine</surname><given-names>H. A.</given-names></name><name><surname>Chang</surname><given-names>S. M.</given-names></name><name><surname>Robins</surname><given-names>H. I.</given-names></name><name><surname>Fink</surname><given-names>K.</given-names></name><name><surname>Deangelis</surname><given-names>L. M.</given-names></name><name><surname>Mehta</surname><given-names>M.</given-names></name><name><surname>Di Tomaso</surname><given-names>E.</given-names></name><name><surname>Drappatz</surname><given-names>J.</given-names></name><name><surname>Kesari</surname><given-names>S.</given-names></name><name><surname>Ligon</surname><given-names>K. L.</given-names></name><name><surname>Aldape</surname><given-names>K.</given-names></name><name><surname>Jain</surname><given-names>R. K.</given-names></name><name><surname>Stiles</surname><given-names>C. D.</given-names></name><name><surname>Egorin</surname><given-names>M. J.</given-names></name><name><surname>Prados</surname><given-names>M. D.</given-names></name></person-group><year>2009</year>. <article-title>Phase II study of imatinib mesylate for
recurrent meningiomas (North American Brain Tumor Consortium study
01&#x2013;08)</article-title>.
<source><italic>Neuro-oncol.</italic></source><volume>11</volume>:
<fpage>853</fpage>&#x2013;<lpage>860</lpage>. doi: <pub-id pub-id-type="doi">10.1215/15228517-2009-010</pub-id><pub-id pub-id-type="pmid">19293394</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
